This year at Europe’s no.1 meeting place for market access, pricing, reimbursement & data professionals, delegates learn how to:

  • Bridge the gap: ensure a fully access-oriented strategy from clinical to commercial
  • Know your stakeholders: map your routes to market for seamless patient access
  • Prove your value: use data and innovative risk-sharing agreements for the reimbursement your portfolio deserves
  • Stay ahead of the market: expert updates on the future evolution of European health policy

A snapshot of 2017’s speaker faculty:

  • Barbara Jaszewski
    Barbara JaszewskiVP Global Pricing & Market Access
  • Martin Price
    Martin PriceVP Health Economics, Market Access & Reimbursement
  • Dana Vigier
    Dana VigierVP Market Access and Government Affairs
    Bristol-Myers Squibb
  • Michael Schroter
    Michael SchroterHead Personalised Reimbursement Models, Global Pricing & Market Access
  • Patrick Hopkinson
    Patrick HopkinsonExecutive Director Worldwide Health Economics and Outcomes Research
  • Pilar Pinilla Dominguez
    Pilar Pinilla DominguezTechnical Adiser
    NICE Scientific Advice
  • Reg Waldeck
    Reg WaldeckVice President Access, Pricing and Health Economics
    Celldex Therapeutics
  • Simone Wyss
    Simone WyssHead EUCan GI Market Access
  • Pamela Bacon
    Pamela BaconExecutive Director Medical Affairs
  • Stefan Holmstrom
    Stefan Holmstrom Executive Director HEOR

The only market access meeting place you'll need to be at this year

It’s our mission to maximise patient access to great medicines – and to be rewarded for it. That mission is true whether you’re in market access, product development, clinical trials or if you’re a payer.

Here’s the new part. It’s also increasingly true whether you work in commercial, R&D or medical functions.

Market access has moved from a vertical unit into a way of life, a skill set that must be learned by every employee, a mantra that must echo through every corridor of your office.

In order to ensure that your patients get the right drug at the right time with the right outcome we must ensure, that from clinical commercial, all employees are focused on delivering this. 

This is where your job has changed radically. You are the earpiece to the payer, spreading these insights across the product pipeline ensuring that their desires are at the forefront of every plan and every initiative, accelarating access for your patients and achieving the reimbursement your drug deserves.

At eyeforpharma’s 2017 flagship access and pricing summit, we’ll show you how to adopt a new and harmonious market access culture. From clinical to commercial, access is now your ultimate goal.

Supporters and attendees in 2017 included:

  • AstraZeneca
  • celgene
  • Exco-InTouch
  • GetReal
    INC Research
  • astellas
    novo nordisk
  • GSK
  • shire
  • Pfizer
  • bristol-myers-squibb
  • Ignite Data
  • vifor-pharma

Our Track-Record of Proven Success

Conferences promise a lot - we know. Below are a few takeaways from the last year's Summit highlighting the valuable insights the attendees took away …

  • call our sessions essential
  • said they will likely return again next year
  • rated the program very well run

What our delegates have said: 

  • Novo Nordisk

    "The event covered most of the key aspects related to RWE. I think, it was very useful. I definitely learned a lot."

    Antonio Ramirez de Arellano, Lead EU-HEOR, Novo Nordisk
  • "Very interesting with excellent informative presentations"

    Janet Valentine, Director of the CPRD, Clinical Practice Research Datalink
  • Bayer

    "This was one of the most relevant and comprehensive conferences, which I have attended in recent years. The speakers and meeting chairs were well selected."

    Karel Mechelse, Market Access Strategy Leader, Bayer
  • Novartis

    "Well worth investing in... a place to exchange views and perspectives"

    Frederic de Reydet, Global Market Access Director, Novartis
  • Eli-Lilly

    "An excellent representation of key European decision makers"

    Myriam Zylberman, Senior Director - EU Payer Strategy, Eli Lilly
  • Janssen

    "A fascinating meeting of diverse speakers who outlined numerous themes around the need to prove the validity and trustworthiness of RWE, versus RCTs, with an emphasis on “real time” versus “real world”. Thank you eyeforpharma!"

    Nigel Hughes, Scientific Director, Janssen

Got any questions or interested in what’s in store for 2018? Get in touch below.

Anthonia Kehinde

Anthonia Kehinde

Global Project Director (Market Access)
+1800 814 3459 x7591 (US)
+44 (0) 207 375 7591 (Global)

2017 Sponsors & Exhibitors

Gold Sponsors

  • Covance
  • Deloitte
  • Epsilon
  • Evidera
  • Highpoint Solutions
  • Quintiles IMS

Silver Sponsors

  • IGES

Supporting Sponsor

  • Caligor